A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 332 participants.

Also called NCT05592275

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 332 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05592275
Other papers using this trial's data
  • Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial Nature medicine, 2025-11 DOI, PubMed 40887551, PMC12618225 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Canada, Czechia, Hungary, Israel, Japan, Poland, Spain, Türkiye, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05592275. Randomized; double masking; primary purpose treatment. Start 2023-02-03 (actual); primary completion 2025-01-22 (actual). Results posted on 2026-02-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
Condition
Heart Failure
Intervention (Drug)
LY3540378
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05592275
Content hash
d9e25ab7baa70803df44781ba486a8522b754952aa2705b090febe535c777952